Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mogamulizumab and Extracorporeal Photopheresis (ECP) for the Treatment of Sézary Syndrome and Erythrodermic Mycosis Fungoides, a Phase 1b/2 Study

NCT04676087 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04676087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mogamulizumab and Extracorporeal Photopheresis (ECP) for the Treatment of Sézary Syndrome and Erythrodermic Mycosis Fungoides, a Phase 1b/2 Study
Lead sponsor
Emory University
Phase
Phase 1/2
Overall status
Terminated
Start date
April 21, 2021
Completion date
October 11, 2023
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mycosis fungoides, primary cutaneous t-cell non-hodgkin lymphoma, sezary syndrome